Drug Trial Radar · NCT01509911
A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment
Last checked: Nov 19, 2026Latest source record: Feb 5, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
99
Actual
Start
Jan 2012
Primary completion
Oct 2016
Study completion Jan 2017
Sponsor
- Lead sponsor
- Tiltan Pharma Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Technostat; Novatrials
- First posted
- Jan 13, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TL-118 is an anti-angiogenic drug combination designed for the treatment of cancer. The investigational product Tl-118 comprises of four well-known active components. The therapy is administrated at a unique dosing regimen that was found to be effective and advantageous in terms of safety. The product is formulated as an oral suspension, conveniently administrated by the patients at home and not requiring medical staff assistance. This Phase II clinical trial aims to evaluate the efficacy, safety and tolerability of TL-118 in Gemcitabine treated Pancreatic Cancer patients
Conditions
- Metastatic Pancreatic Cancer
Interventions
TL-118Drug
TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles.
GemcitabineDrug
Monthly cycles of 3 weekly treatments a month and one week off of treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease Control Rate as defined by Percentage of patients experiencing a Complete Response or a Partial Response or a Stable Disease according to RECIST measured at 16 weeks after treatment initiationTime frame: 16 weeks after treatment initiation
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
Emory Clinic
Atlanta, Georgia
White Plains Hospital
White Plains, New York
HaEmek Medical Center
Afula, Israel
Soroka Medical Center
Beersheba, Israel
Hillel Yaffe Medical Center
Hadera, Israel
Rambam Medical Center
Haifa, Israel
Hadassah Medical Center
Jerusalem, Israel
Sheba Medical Center
Ramat Gan, Israel
Sourasky Medical Center
Tel Aviv, Israel
Assaf Harofe Medical Center
Tsrifin, Zerifin, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.